JPRN-jRCTs031220726招募中2 期
Efficacy of romosozumab and post-alendronate therapy on osteogenesis imperfecta
Ito Nobuaki0 个研究点目标入组 20 人开始时间: 2023年3月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Those who are diagnosed with osteogenesis imperfecta with type I collagen mutations (COL1A1, COL1A2) based on genetic testing and with concurrent osteoporosis
- •2. Age: Those who are 20 years of age or older at the time of obtaining consent
- •3. Gender: Any gender
- •4. Those who have received a full explanation of the study and have given written consent of their own free will based on a full understanding of the study
- •5. Those who can make outpatient visits in accordance with the research implementation schedule
排除标准
- •1. Patients participating in other clinical trials at the time consent is obtained
- •2. Patients who are contraindicated for the use of romosozumab and alendronate
- •- Patients with a history of hypersensitivity to romosozumab
- •- Patients with disorders that slow esophageal transit such as esophageal stricture or achalasia
- •- Patients unable to sit or stand for more than 30 minutes
- •- Patients with a history of hypersensitivity to alendronate or other bisphosphonates
- •- Patients with hypocalcemia
- •3. Those with serious liver disorder, renal disorder, or cardiovascular disease (JCOG CTCAE version 5.0 Grade 3 will be used as a reference)
- •4. Those with malignant tumors
- •5. Those who have a history of serious drug allergy such as anaphylactic shock or a history of serious side effects
- •6. Those who have participated in a clinical trial and taken an investigational drug within 6 months before obtaining informed consent
- •7. Those who plan to take osteoporosis drugs such as bisphosphonates and denosumab from the time of obtaining informed consent to the end of the study period
- •8. Those who have not passed 6 months or more since the last dose of denosumab
- •9. Those who have not passed one year or more since the last dose of zoledronic acid hydrate
- •10. Those who are pregnant, may become pregnant, or are breastfeeding
- •11. Those who are judged unfavorable for participation in this study by the principal investigator or sub investigator (for example, patients who are difficult to perform tests due to dementia, patients who refuse to take blood samples, etc.)
研究者
相似试验
招募中
不适用
Evaluation of efficacy and safety of romosozumab administration group and ibandronate sodium hydrate administration group for osteoporosis patients after denosumab treatmentosteoporosisJPRN-UMIN000037394Shinshu University School of Medicine Dept. of Orthopaedic Surgery60
进行中（未招募）
1 期
Efficacy of Olaratumab and Re-Treatment with Doxorubicin in anthracycline pretreated, advanced soft tissue sarcoma patients.locally advanced (unresectable) or metastatic soft tissue sarcomaMedDRA version: 15.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001124-20-DEIKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest60
已完成
不适用
Effect of subsequence treatment after romosozumab in patietns with osteoporosis: open-label, randomised contorlled trialOsteoporosisJPRN-UMIN000040132Department of Orthopaedic Surgery, Showa University School of Medicine105
招募中
不适用
The effects of denosumab compared with alendronate on glucocorticoid-induced osteoporosis in patients with malignant lymphomaglucocorticoid-induced osteoporosis in patients with malignant lymphomaJPRN-UMIN000038881Toyama University Hospital Department of Hematology100
招募中
不适用
Denosumab and Alendronate, Examination of the effective of Glucocorticoid-induced OsteoporosisSteroid induced osteoporosisJPRN-UMIN000033122The First Department of Internal Medicine University of Occupational and Environmental Health, Japan, School of Medicine200